The general objective of this project is to evaluate the value of cell-free DNA circulating in plasma as a marker of tumor evolution in patients with high-grade gliomas and meningiomas. To this end, we propose to longitudinally collect four samples of plasma at the following time points: * T0: before surgery; * T1: one month after surgery; * T2: one month after the end of radiotherapy; * T3 at the time of radiological progression. The goal is to evaluate whether changes in plasma concentration of circulating cell-free DNA can help predict progression-free survival, overall survival, and response to therapies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
cfDNA correlation with PFS
Timeframe: 1-3 days before surgery until disease progression (or at month 12 after surgery in the absence of disease progression)